As MedSurg demand rises, Boston Scientific and Medtronic compete for dominance. Which stock shows stronger growth momentum now?

Abbott Laboratories flexes its market muscle with consistent gains and an enviable track record of long-term growth. Its ...

Boston Scientific’s Neuromodulation segment is charging ahead with a caffeinated jolt of momentum, posting 6.8% operational ...

Boston Scientific’s BSX Neuromodulation business develops and manufactures devices to treat various neurological movement ...

But now, also like pacemakers, technological advances allow the devices to individualize their functionality. In the case of Medtronic's new product, it can use a person's individual brain signals ...

With more than 40,000 DBS patients served worldwide with Medtronic Percept™ devices, BrainSense™ Adaptive DBS presents the largest commercial launch (by several magnitudes) of BCI technology ...

Seventeen years before Medtronic’s recent FDA approval. for the world’s first adaptive deep brain stimulation (DBS) system for Parkinson’s disease, Scott Stanslaski was just starting his work on the ...

Mumbai: Medtronic, a healthcare technology company, has received FDA approval for its Percep RC neurostimulator, now available in India.This device, designed for Deep Brain Stimulation (DBS ...

Medtronic has published preliminary data from a study of its adaptive deep brain stimulation (aDBS) device, Percept PC neurostimulator, in patients living with Parkinson’s disease. The adaptive DBS ...

Medtronic plc (NYSE: MDT) is a leading global medical device maker in the medical sector. Its innovative and critical medical ...

Reitmeier pointed to a recent adaptive DBS study at University of California San Francisco that used a research version of Medtronic’s neurostimulation devices. Researchers developed an adaptive DBS ...